Augustine Therapeutics will present preclinical data on an HDAC6 inhibitor for heart failure with preserved ejection fraction at the American Diabetes Association conference. The selective HDAC6 inhibitor represents a mechanistic approach to a prevalent cardiometabolic phenotype where ejection fraction remains normal despite functional impairment.
Key Points
- HDAC6 inhibitor showed efficacy in heart failure with preserved ejection fraction models
- Non-hydroxamate chemotype designed for chronic disease safety and selectivity
- Addresses cardiometabolic overlap between heart failure and metabolic dysfunction
Longevity Analysis
Heart failure with preserved ejection fraction has emerged as a distinct clinical challenge in aging populations, particularly those with metabolic dysfunction. HDAC6 inhibition targets histone deacetylase activity, a process central to cellular stress adaptation and energy metabolism. This mechanistic approach addresses how the heart maintains function under metabolic strain—a critical distinction from traditional ejection fraction-based therapies. The cardiometabolic frame suggests this candidate may influence how the body's energy production and circulatory systems respond to chronic metabolic stress, potentially relevant for individuals navigating the intersection of diabetes and cardiac aging.
Original published by Longevity.Technology.